देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
VERAPAMIL HYDROCHLORIDE
BGP PHARMA ULC
C08DA01
VERAPAMIL
180MG
TABLET (EXTENDED-RELEASE)
VERAPAMIL HYDROCHLORIDE 180MG
ORAL
100
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0113846004; AHFS:
APPROVED
2015-01-07
_ISOPTIN®_ _ _ _SR (verapamil hydrochloride) Product Monograph_ _ _ _Page 1 of 42 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ISOPTIN®SR verapamil hydrochloride sustained-release tablets 120 mg, 180 mg and 240 mg Manufacturer’s Standard _ _ Antihypertensive Agent BGP Pharma ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Initial Authorization: December 18, 2014 Date of Revision: December 7, 2021 Submission Control Number: 253349 _ _ _ISOPTIN®_ _ _ _SR (verapamil hydrochloride) Product Monograph_ _ _ _Page 2 of 42_ RECENT MAJOR LABEL CHANGES CONTRAINDICATIONS WARNINGS AND PRECAUTIONS October 2019 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 INDICATIONS ...........................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics.............................................................................................................4 CONTRAINDICATIONS ..............................................................................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations .........................................................................................5 4.2 Recommended Dose and Dosage Adjustment.......................................................6 4.4 Administration....................................................................... पूरा दस्तावेज़ पढ़ें